RESUMO
We assessed the effectiveness and safety of switching to generic dolutegravir/lamivudine (DTG/3TC) among People living with Human Immunodeficiency Virus (PWH) in Western India. In this single-center, retrospective observational study, PWH, who switched to DTG/3TC, were followed for virologic, immunologic, and clinical effectiveness, and safety, including weight changes, hyperglycemia, and dyslipidemia. Multivariate linear mixed-effects models were used to predict average change in weight adjusted for age, sex, duration of previous antiretroviral (ARV) regimens, and baseline weight. From May 2017 to July 2022, out of 434 PWH switched to DTG/3TC, 304 with at least 1 follow-up visit were included. Median [interquartile range (IQR)] age was 54 (IQR 49-61) years and 70.1% were male. Prevalence of baseline comorbidities was 57.9% (hypertension-41.5%, chronic kidney disease-40.9%, and diabetes mellitus-18.8%). Reasons for switch were affordability (47.4%), desire for simplification (41.8%), ARV toxicities (19.1%), and concern about potential toxicities (10.2%). Median (IQR) duration of follow-up on DTG/3TC was 40 (IQR 31-49) weeks. No virologic failure was observed. Rates of virologic suppression [viral load (VL) ≤20 copies/mL or target not detected (TND)] at 12, 24, 48, 72, 96 and 120 weeks were 95.2%, 95.9%, 90%, 100%, 81.3%, and 88.4%, respectively. Only 9 (3%) PWH permanently discontinued DTG/3TC. Predicted adjusted mean weight gain of +3.3 kg was observed at 96 weeks. Switching from tenofovir disoproxil fumarate (TDF)/emtricitabine or lamivudine (XTC)/non-nucleoside reverse transcriptase inhibitor (NNRTI) and duration on DTG/3TC were significantly associated with weight gain. Apart from trend in worsening hyperglycemia (nine PWH with new onset diabetes), no clinically significant change in lipids and estimated glomerular filtration rate (eGFR) was documented. Switching to DTG/3TC is an effective and safe option among virologically suppressed PWH with high comorbidity burden in India. In view of the several advantages of DTG/3TC, it may be considered for potential scale-up in the right population, both in private and public health care settings in India.
Assuntos
Fármacos Anti-HIV , Infecções por HIV , HIV-1 , Hiperglicemia , Piperazinas , Piridonas , Masculino , Humanos , Pessoa de Meia-Idade , Feminino , Lamivudina/efeitos adversos , Fármacos Anti-HIV/efeitos adversos , Infecções por HIV/tratamento farmacológico , Oxazinas/uso terapêutico , Compostos Heterocíclicos com 3 Anéis/efeitos adversos , Antirretrovirais/uso terapêutico , Aumento de Peso , Hiperglicemia/tratamento farmacológicoRESUMO
Vapor-liquid equilibrium (VLE) data for the binary systems tetrahydrofuran (THF) + acetic acid (AA) and THF + trichloroethylene (TCE) were measured under isobaric conditions using an ebulliometer. The boiling temperatures for the systems (THF + AA/THF + TCE) are reported for 13/15 compositions and five/six different pressures ranging from 50.2/60.0 to 101.1/101.3 kPa, respectively. The THF + AA system shows simple phase behavior with no azeotrope formation. The THF + TCE system does not exhibit azeotrope formation but seems to have a pinch point close to the pure end of TCE. The nonrandom two-liquid (NRTL) and universal quasichemical (UNIQUAC) activity coefficient models were used to accurately fit the binary (PTx) data. Both models were able to fit the binary VLE data satisfactorily. However, the NRTL model was found to be slightly better than UNIQUAC model in fitting the VLE data for both systems. The results can be used for designing liquid-liquid extraction and distillation processes involving mixtures of THF, AA, and TCE.
RESUMO
Vapor pressure refers to the pressure exerted by the vapor phase in thermodynamic equilibrium with either its liquid or solid phase. An important class of active matter is field-driven colloids. A suspension of dipolar colloids placed in a high-frequency rotating magnetic field undergoes a nonequilibrium phase transition into a dilute and dense phase, akin to liquidvapor coexistence in a simple fluid. Here, we compute the vapor pressure of this colloidal fluid. The number of particles that exist as the dilute bulk phase versus condensed cluster phases can be directly visualized. An exponential relationship between vapor pressure and effective temperature is determined as a function of applied field strength, analogous to the thermodynamic expression between vapor pressure and temperature found for pure liquids. Additionally, we demonstrate the applicability of Kelvin's equation to this field-driven system. In principle, this appears to be in conflict with macroscopic thermodynamic assumptions due to the nonequilibrium and discrete nature of this colloidal system. However, the curvature of the vaporliquid interface provides a mechanical equilibrium characterized by interfacial tension that connects the condensed clusters observed with these active fluids to classical colligative fluid properties.
RESUMO
BACKGROUND: Long-COVID is emerging as a significant problem among individuals who recovered from COVID-19. Scant information is available on the prevalence, characteristics, and risk factors for long-COVID among people living with HIV (PLHIV). SETTING: A tertiary level, private, HIV clinic in western India. METHODS: A prospective, observational study was conducted to assess the prevalence of long-COVID among PLHIV. Long-COVID was defined as the presence of at least one symptom after 30 days of illness onset. A questionnaire for assessing general, cardiorespiratory, neuro-psychiatric, and gastro-intestinal symptoms was used to screen individuals with history of confirmed COVID-19. Data on demographics, HIV-related variables, comorbidities, and severity of COVID-19 were abstracted from electronic medical records. Univariate and multivariate logistic regression were used to identify risk factors for long-COVID. RESULTS: Ninety-four PLHIV were screened for long-COVID. Median (interquartile range [IQR]) age was 51 (47-56) years and 73.4% were males. The majority (76.6%) had a history of asymptomatic-mild COVID-19 illness. The prevalence of long-COVID was 43.6% (95% confidence interval [CI], 33.4-54.2). Moderate-severe COVID-19 illness was significantly associated with long-COVID (adjusted odds ratio, 4.7; 95% CI, 1.4-17.9; p = .016). Among individuals with long-COVID, cough (22.3%) and fatigue (19.1%) were the commonest symptoms. The median (IQR) duration for resolution of symptoms was 15 (7-30) days. Ten individuals (10.6%) had persistent symptoms at a median of 109 days since the onset of COVID-19. CONCLUSION: Long-COVID is common among PLHIV with moderate-severe acute COVID-19 illness. There is a need for integration of long-COVID diagnosis and care services within antiretroviral therapy clinics for PLHIV with COVID-19.
Assuntos
COVID-19/complicações , Infecções por HIV , COVID-19/epidemiologia , Feminino , Infecções por HIV/epidemiologia , Humanos , Índia/epidemiologia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Síndrome de COVID-19 Pós-AgudaRESUMO
A retrospective cohort study was conducted to assess clinical characteristics and outcomes of coronavirus disease-19 (COVID-19) among people living with HIV (PLHIV) in western India. Out of 86 PLHIV with COVID-19 illness, 19.7% had severe/critical illness and 6 (6.9%) individuals died. Median (interquartile range) age was 51 (47-56) years and 77.6% were male. Eighty-five PLHIV were on antiretroviral treatment with 98% having a viral load <200 copies/mL. Hypertension (HTN) (38.3%) and diabetes mellitus (17.4%) were commonest comorbidities. Fifty-eight percent PLHIV were hospitalized while 6.9% individuals needed intensive care. Presence of medical comorbidity was significantly associated with severe/critical COVID-19, whereas HTN was significantly associated with mortality. Recovery from COVID-19 was documented in 93% PLHIV. In conclusion, PLHIV in western India have similar COVID-19 clinical outcomes as compared with those reported historically among general population. Presence of medical comorbidities rather than HIV-related disease characteristics is associated with severe COVID-19 illness.
Assuntos
COVID-19/epidemiologia , Infecções por HIV/epidemiologia , COVID-19/diagnóstico , Comorbidade , Feminino , Humanos , Índia/epidemiologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , SARS-CoV-2RESUMO
Magnetically-guided colloidal assembly has proven to be a versatile method for building hierarchical particle assemblies. This review describes the dipolar interactions that govern superparamagnetic colloids in time-varying magnetic fields, and how such interactions have guided colloidal assembly into materials with increasing complexity that display novel dynamics. The assembly process is driven by magnetic dipole-dipole interactions, whose strength can be tuned to be attractive or repulsive. Generally, these interactions are directional in static external magnetic fields. More recently, time-varying magnetic fields have been utilized to generate dipolar interactions that vary in both time and space, allowing particle interactions to be tuned from anisotropic to isotropic. These interactions guide the dynamics of hierarchical assemblies of 1-D chains, 2-D networks, and 2-D clusters in both static and time-varying fields. Specifically, unlinked and chemically-linked colloidal chains exhibit complex dynamics, such as fragmentation, buckling, coiling, and wagging phenomena. 2-D networks exhibit controlled porosity and interesting coarsening dynamics. Finally, 2-D clusters have shown to be an ideal model system for exploring phenomena related to statistical thermodynamics. This review provides recent advances in this fast-growing field with a focus on its scientific potential.
RESUMO
Phase separation processes are widely utilized to assemble complex fluids into novel materials. These separation processes can be thermodynamically driven due to changes in concentration, pressure, or temperature. Phase separation can also be induced with external stimuli, such as magnetic fields, resulting in novel nonequilibrium systems. However, how external stimuli influence the transition pathways between phases has not been explored in detail. Here, we describe the phase separation dynamics of superparamagnetic colloids in time-varying magnetic fields. An initially homogeneous colloidal suspension can transition from a continuous colloidal phase with voids to discrete colloidal clusters, through a bicontinuous phase formed via spinodal decomposition. The type of transition depends on the particle concentration and magnitude of the applied magnetic field. The spatiotemporal evolution of the microstructure during the nucleation and growth period is quantified by analyzing the morphology using Minkowski functionals. The characteristic length of the colloidal systems was determined to correlate with system variables such as magnetic field strength, particle concentration, and time in a power-law scaling relationship. Understanding the interplay between particle concentration and applied magnetic field allows for better control of the phases observed in these magnetically tunable colloidal systems.
RESUMO
BACKGROUND: Data on the use of dolutegravir for treatment of HIV-2 infection are limited. OBJECTIVES: To assess the effectiveness of dolutegravir in people living with HIV-2 (PLHIV-2). METHODS: A retrospective chart review was performed in two clinics in Western India. PLHIV-2 initiated on dolutegravir-based regimens were included. Response to treatment in both treatment-naive (TN) and treatment-experienced (TE; substitution and not in the context of failure) was assessed by CD4 counts and HIV-2 viral load (VL) in a proportion of individuals. The primary objective was to assess immunological effectiveness (absence of a drop in absolute CD4 counts by more than 30% of baseline). Change in absolute CD4 counts was assessed by fitting a mixed-effects model. RESULTS: Sixty-two PLHIV-2 treated with dolutegravir were included. The immunological effectiveness rates (95% CI) were 91.9% (82.4%-96.5%), 92% (81.1%-96.8%) and 91.6% (64.6%-98.5%) amongst all, TE and TN individuals, respectively. Median change in absolute CD4 counts at 6, 12 and 18 months were +29 cells/mm3, +101 cells/mm3 and +72 cells/mm3, respectively. The virological effectiveness rates (HIV-2 VL <100 copies/mL) (95% CI) for all, TE and TN individuals were 88.8% (74.6%-95%), 89.6% (73.6%-96.4%) and 85.7% (48.6%-97.4%), respectively. Three clinical events were documented: spinal tuberculosis, relapsed non-Hodgkin's lymphoma and herpes simplex virus retinitis. One individual reported self-limiting somnolence. CONCLUSIONS: Dolutegravir was well tolerated and associated with immunological, virological and clinical effectiveness in both TN and TE PLHIV-2 in a large cohort from Western India. Dolutegravir-based ART is an excellent option for treatment of individuals with HIV-2 infection.
Assuntos
Infecções por HIV , HIV-2 , Infecções por HIV/tratamento farmacológico , Compostos Heterocíclicos com 3 Anéis/uso terapêutico , Humanos , Índia , Oxazinas , Piperazinas , Piridonas , Estudos Retrospectivos , Carga ViralRESUMO
INTRODUCTION: Cotrimoxazole (CTX) is recommended as prophylaxis against Pneumocystis jiroveci pneumonia, malaria and other serious bacterial infections in HIV-infected patients. Despite its in vitro activity against Mycobacterium tuberculosis, the effects of CTX preventive therapy on tuberculosis (TB) remain unclear. METHODS: Adults living with HIV enrolled in a regional observational cohort in Asia who had initiated combination antiretroviral therapy (cART) were included in the analysis. Factors associated with new TB diagnoses after cohort entry and survival after cART initiation were analysed using Cox regression, stratified by site. RESULTS: A total of 7355 patients from 12 countries enrolled into the cohort between 2003 and 2016 were included in the study. There were 368 reported cases of TB after cohort entry with an incidence rate of 0.99 per 100 person-years (/100 pys). Multivariate analyses adjusted for viral load (VL), CD4 count, body mass index (BMI) and cART duration showed that CTX reduced the hazard for new TB infection by 28% (HR 0.72, 95% CI l 0.56, 0.93). Mortality after cART initiation was 0.85/100 pys, with a median follow-up time of 4.63 years. Predictors of survival included age, female sex, hepatitis C co-infection, TB diagnosis, HIV VL, CD4 count and BMI. CONCLUSIONS: CTX was associated with a reduction in the hazard for new TB infection but did not impact survival in our Asian cohort. The potential preventive effect of CTX against TB during periods of severe immunosuppression should be further explored.
Assuntos
Infecções por HIV/complicações , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Tuberculose/prevenção & controle , Adulto , Fármacos Anti-HIV/uso terapêutico , Antirretrovirais/uso terapêutico , Ásia/epidemiologia , Estudos de Coortes , Feminino , Infecções por HIV/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Tuberculose/epidemiologia , Tuberculose/etiologia , Tuberculose/mortalidade , Carga ViralRESUMO
PURPOSE: Renal disease is common among people living with human immunodeficiency virus (HIV). However, there is limited information on the incidence and risk factors associated with renal dysfunction among this population in Asia. METHODS: We used data from the TREAT Asia HIV Observational Database. Patients were included if they started antiretroviral therapy during or after 2003, had a serum creatinine measurement at antiretroviral therapy initiation (baseline), and had at least 2 follow-up creatinine measurements taken ≥3 months apart. Patients with a baseline estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73 m2 were excluded. Chronic kidney disease was defined as 2 consecutive eGFR values ≤60 mL/min/1.73 m2 taken ≥3 months apart. Generalized estimating equations were used to identify factors associated with eGFR change. Competing risk regression adjusted for study site, age and sex, and cumulative incidence plots were used to evaluate factors associated with chronic kidney disease (CKD). RESULTS: Of 2547 patients eligible for this analysis, tenofovir was being used by 703 (27.6%) at baseline. Tenofovir use, high baseline eGFR, advanced HIV disease stage, and low nadir CD4 were associated with a decrease in eGFR during follow-up. Chronic kidney disease occurred at a rate of 3.4 per 1000 patient/years. Factors associated with CKD were tenofovir use, old age, low baseline eGFR, low nadir CD4, and protease inhibitor use. CONCLUSIONS: There is an urgent need to enhance renal monitoring and management capacity among at-risk groups in Asia and improve access to less nephrotoxic antiretrovirals.
Assuntos
Fármacos Anti-HIV/efeitos adversos , Taxa de Filtração Glomerular/efeitos dos fármacos , Infecções por HIV/tratamento farmacológico , Rim/efeitos dos fármacos , Insuficiência Renal Crônica/epidemiologia , Adulto , Fatores Etários , Fármacos Anti-HIV/administração & dosagem , Ásia/epidemiologia , Creatinina/sangue , Feminino , Seguimentos , Taxa de Filtração Glomerular/fisiologia , Humanos , Incidência , Rim/fisiopatologia , Masculino , Insuficiência Renal Crônica/sangue , Insuficiência Renal Crônica/induzido quimicamente , Insuficiência Renal Crônica/fisiopatologia , Fatores de Risco , Tenofovir/administração & dosagem , Tenofovir/efeitos adversos , Fatores de TempoRESUMO
BACKGROUND: There is no information on the clinical effectiveness of Maraviroc (MVC) amongst People Living with HIV (PLHIV) in India infected with HIV-1 Subtype C viruses. METHODS: We conducted a retrospective chart review of adult PLHIV on MVC based Antiretroviral (ARV) regimens for at least 6 months. Maraviroc was initiated amongst PLHIV with documented R5 tropic viruses (determined by in-house population sequencing of the V3 loop in triplicate and interpreted using the Geno2Pheno algorithm) in combination with an Optimized Background regimen (designed using genotypic resistance testing and past ARV history). Plasma viral loads (PVL) are performed 6 months post-initiation and annually thereafter. Primary outcome d. Median duration on MVC treatment was 1.8 years (range 1-2.9 years) while median duration of ART prior to switching to MVC was 13 years. Maraviroc was combined with Darunavir/ritonavir (DRV/r) (n=10), Atazanavir/r (ATV/r) (n=2) and Lopinavir/r (LPV/r) (n=1). All PLHIV were infected with HIV-1 Subtype C. Only 23.3% PLHIV achieved virologic suppression at 6 months and sustained it for 2.3 years. Median CD4 count change from baseline was +117 (n=13), +228 (n=10), +253 (n=9), and +331 (n=4) at 6, 12, 18 and 24 months respectively. Repeat tropism among patients with virologic failure demonstrated R5 virus. CONCLUSIONS: High rates of virologic failure was seen when MVC was used amongst treatment experienced PLHIV infected with HIV-1 Subtype C in India. was the proportion of PLHIV with virologic success (PVL<50 copies/ml) at last follow up visit. RESULTS: Data on 13 PLHIV were analyze.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , HIV-1/efeitos dos fármacos , Maraviroc/uso terapêutico , Falha de Tratamento , Adulto , Contagem de Linfócito CD4 , Darunavir/uso terapêutico , Quimioterapia Combinada/efeitos adversos , Feminino , Inibidores da Fusão de HIV/uso terapêutico , Infecções por HIV/sangue , HIV-1/genética , Humanos , Índia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Ritonavir/uso terapêutico , Terapia de Salvação , Carga Viral/efeitos dos fármacosAssuntos
Farmacorresistência Viral , Infecções por HIV/virologia , Inibidores de Integrase de HIV/farmacologia , Integrase de HIV/genética , HIV/enzimologia , Mutação de Sentido Incorreto , Raltegravir Potássico/farmacologia , Adulto , Feminino , HIV/genética , HIV/isolamento & purificação , Infecções por HIV/tratamento farmacológico , Inibidores de Integrase de HIV/uso terapêutico , Humanos , Índia , Masculino , Pessoa de Meia-Idade , Mutação , Raltegravir Potássico/uso terapêutico , Estudos Retrospectivos , Centros de Atenção Terciária , Falha de TratamentoRESUMO
Convective deposition is a scalable method for directing colloidal self-assembly. Ordered layers of deposited particles have numerous applications as advanced materials for optical devices and membranes. Over the past 20years, a simple mass balance derived by Dimitrov and Nagayama has been widely used for relating film thickness to deposition velocity, suspension concentration and evaporation rate and particle size. This balance works well for a small range of deposition velocities, but it fails to predict the coating thickness over a broader range. Specifically, in this balance the length scale related to drying is not well-posed and the drying length generally thought to be roughly constant. This work derives an analytical expression for the drying length in convective deposition for a more general set of conditions by considering the resistance to flow through the deposited particles. This analysis allows prediction of coating thickness over a wider range of velocities from low density coatings to multilayer particle assemblies.
RESUMO
Chronic stress has been associated with a number of illnesses, including obesity. Ashwagandha is a well-known adaptogen and known for reducing stress and anxiety in humans. The objective of this study was to evaluate the safety and efficacy of a standardized root extract of Ashwagandha through a double-blind, randomized, placebo-controlled trial. A total of 52 subjects under chronic stress received either Ashwagandha (300 mg) or placebo twice daily. Primary efficacy measures were Perceived Stress Scale and Food Cravings Questionnaire. Secondary efficacy measures were Oxford Happiness Questionnaire, Three-Factor Eating Questionnaire, serum cortisol, body weight, and body mass index. Each subject was assessed at the start and at 4 and 8 weeks. The treatment with Ashwagandha resulted in significant improvements in primary and secondary measures. Also, the extract was found to be safe and tolerable. The outcome of this study suggests that Ashwagandha root extract can be used for body weight management in adults under chronic stress.
Assuntos
Peso Corporal/fisiologia , Extratos Vegetais/uso terapêutico , Estresse Psicológico/terapia , Adulto , Doença Crônica , Método Duplo-Cego , Feminino , Humanos , Hidrocortisona/sangue , Masculino , Pessoa de Meia-Idade , Fitoterapia , Aumento de Peso , Adulto JovemRESUMO
Rapid convective deposition is used to assemble nanoparticle coatings from suspension, with controllable thickness. Varying film thickness generates stress-induced linear cracks with highly monodisperse spacing. Film thickness is controlled through mechanical means, suspension volume fraction, and the use of applied thermal gradients. These cracks extend in the deposition direction, and a uniform crack spacing from 2 to 160µm is observed. The nanoparticle film thickness is the relevant length scale for hydrodynamic flow, and films will crack with this spacing, in a characteristic manner to minimize the system energy and capillary stresses. As expected from this energy minimization problem and relevant theory, the correlation between coating thickness and crack spacing is highly linear. Because this process is continuous, continuous cracks have potential as a high-throughput method of fabricating nanoscale channels for microfluidics and MEMS.
RESUMO
BACKGROUND AND OBJECTIVES: Excessive and prolonged work-related stress has always been a cause for burnout among healthcare professionals. This has led to emotional, mental, and physical exhaustion. This survey was conducted to assess the burnout among medical practitioners using the abbreviated Maslach Burnout Inventory (aMBI) and Burnout Clinical Subtype Questionnaire (BCSQ-12) scales. MATERIALS AND METHODS: A cross-sectional survey was conducted among 482 registered medical practitioners across India. A questionnaire consisting of 25 socio-demographic and occupational questions related to aMBI and BCSQ-12 scales was used to assess the burnout. The distribution of responses for each variable was examined using frequencies and percentages among the subgroups to find out the burnout levels of various components of the scales. RESULTS: High burnout levels were uniformly recorded for the entire population. For the aMBI, 45.02% (n = 217) and 65.98% (n = 318) of the participants scored high on the emotional exhaustion and depersonalization scales, respectively, whereas 87.14% (n = 420) scored low on the personal accomplishment scale and 62.86% (n = 303) and 11.41% (n = 55) had medium and low scores on the satisfaction with the medical practice scale. The BCSQ-12 scale showed the mean values of 15.89, 11.56, and 10.28 on a scale of 28 for overload, lack of development, and neglect subtypes, respectively, whereas, satisfaction with the financial compensation item showed a mean value of 3.79 on a scale of seven. All these values indicate high levels of burnout. CONCLUSION: The results suggest high levels of burnout in all domains of aMBI and BCSQ-12 scales in all the occupational and socio-demographic groups of medical practitioners and warrant immediate actions to address this issue.
RESUMO
BACKGROUND: Withania somnifera (ashwagandha) is a prominent herb in Ayurveda. This study was conducted to examine the possible effects of ashwagandha root extract consumption on muscle mass and strength in healthy young men engaged in resistance training. METHODS: In this 8-week, randomized, prospective, double-blind, placebo-controlled clinical study, 57 young male subjects (18-50 years old) with little experience in resistance training were randomized into treatment (29 subjects) and placebo (28 subjects) groups. Subjects in the treatment group consumed 300 mg of ashwagandha root extract twice daily, while the control group consumed starch placebos. Following baseline measurements, both groups of subjects underwent resistance training for 8 weeks and measurements were repeated at the end of week 8. The primary efficacy measure was muscle strength. The secondary efficacy measures were muscle size, body composition, serum testosterone levels and muscle recovery. Muscle strength was evaluated using the 1-RM load for the bench press and leg extension exercises. Muscle recovery was evaluated by using serum creatine kinase level as a marker of muscle injury from the effects of exercise. RESULTS: Compared to the placebo subjects, the group treated with ashwagandha had significantly greater increases in muscle strength on the bench-press exercise (Placebo: 26.4 kg, 95% CI, 19.5, 33.3 vs. Ashwagandha: 46.0 kg, 95% CI 36.6, 55.5; p = 0.001) and the leg-extension exercise (Placebo: 9.8 kg, 95% CI, 7.2,12.3 vs. Ashwagandha: 14.5 kg, 95 % CI, 10.8,18.2; p = 0.04), and significantly greater muscle size increase at the arms (Placebo: 5.3 cm(2), 95% CI, 3.3,7.2 vs. Ashwagandha: 8.6 cm(2), 95% CI, 6.9,10.8; p = 0.01) and chest (Placebo: 1.4 cm, 95% CI, 0.8, 2.0 vs. Ashwagandha: 3.3 cm, 95% CI, 2.6, 4.1; p < 0.001). Compared to the placebo subjects, the subjects receiving ashwagandha also had significantly greater reduction of exercise-induced muscle damage as indicated by the stabilization of serum creatine kinase (Placebo: 1307.5 U/L, 95% CI, 1202.8, 1412.1, vs. Ashwagandha: 1462.6 U/L, 95% CI, 1366.2, 1559.1; p = 0.03), significantly greater increase in testosterone level (Placebo: 18.0 ng/dL, 95% CI, -15.8, 51.8 vs. Ashwagandha: 96.2 ng/dL, 95% CI, 54.7, 137.5; p = 0.004), and a significantly greater decrease in body fat percentage (Placebo: 1.5%, 95% CI, 0.4%, 2.6% vs. Ashwagandha: 3.5%, 95% CI, 2.0%, 4.9%; p = 0.03). CONCLUSION: This study reports that ashwagandha supplementation is associated with significant increases in muscle mass and strength and suggests that ashwagandha supplementation may be useful in conjunction with a resistance training program.
Assuntos
Suplementos Nutricionais , Força Muscular/efeitos dos fármacos , Músculo Esquelético/efeitos dos fármacos , Resistência Física/efeitos dos fármacos , Preparações de Plantas/farmacologia , Treinamento Resistido , Withania , Adulto , Composição Corporal , Método Duplo-Cego , Exercício Físico , Humanos , Masculino , Força Muscular/fisiologia , Músculo Esquelético/fisiologia , Resistência Física/fisiologia , Preparações de Plantas/uso terapêutico , Fenômenos Fisiológicos da Nutrição Esportiva , Resultado do TratamentoRESUMO
Particle-particle and particle-substrate interactions play a crucial role in capillary driven convective self-assembly for continuous deposition of particles. This systematic study demonstrates the nontrivial effects of varying surface charge and ionic strength of monosized silica microspheres in water on the quality of the deposited monolayer. Increase in particle surface charge results a broader range of parameters that result in monolayer deposition which can be explained considering the particle-substrate electrostatic repulsion in solution. Resulting changes in the coating morphology and microstructure at different solution conditions were observed using confocal microscopy enabling correlation of order to disorder transitions with relative particle stability. These results, in part, may explain similar results seen by Muangnapoh et al., 2013 in vibration-assisted convective deposition.
RESUMO
Convective deposition is widely used to deposit a highly ordered and uniform layer of monosized particles from solution by drawing the particles into an advancing thin film that uses capillary forces to define their local orientation. This process is often plagued by the formation of streaks, the regions where particles accumulate due to a local flux inhomogeneity. Flow occurs in the direction orthogonal to the deposition direction and parallel to the substrate near the streaks due to enhanced evaporation where particles have accumulated. This study investigates the formation of streaks nucleated from seeds or defects having prescribed dimensions and spacing across the substrate. The formation and spacing of both seeded and spontaneous streaks are characterized and were observed to be roughly dictated by the suspending fluid capillary length. Thus, spontaneously forming streaks can be suppressed by reducing the spacing to less than twice the critical length. Likewise, the conditions for maximum density or minimal spacing of streaks are also shown.
RESUMO
BACKGROUND: Data on the renal safety of Tenofovir (TDF) in Low and Middle Income Countries (LMICs) is scarce. We compared development of various forms of renal impairment with use of TDF-containing antiretroviral therapy (ART) between a cohort from the Institute of Infectious Diseases (IID) Pune, Western India and the Royal Free Hospital (RFH) London, UK. METHODS: This is a retrospective analysis of change in estimated glomerular filtration rates (eGFRs) at 6, 12 and 24 months post TDF initiation using the Modification of Diet in Renal Disease (MDRD) equation. In people living with Human Immunodeficiency virus (PLHIV) with pre-TDF eGFR > 90 ml/min/1.73 m2 time to development of and factors associated with progression to eGFR < 60 ml/min/1.73 m2 were calculated using standard survival methods. RESULTS: A total of 574 (59% Caucasian) at the RFH, and 708 (100% Indian ethnicity) PLHIV from IID were included. Baseline median eGFR were similar; RFH 102 (IQR 89, 117), IID 100 (82, 119). At 24 months, mean (SD) decline in eGFR was -7(21) at RFH (p < 0.0001) and -7(40) at IID (p = 0.001). Amongst those with pre-TDF eGFR > 90 ml/min/1.73 m2 PLHIV at IID were more likely to develop an eGFR < 60 ml/min/1.73 m2 (aHR = 7.6 [95% CI 3.4, 17.4] p < 0.0001) and had a faster rate of progression estimated using Kaplan Meier methods. Risk factors included age (per 10 years older: aHR = 2.21 [1.6, 3.0] p < 0.0001) and receiving concomitant ritonavir boosted Protease Inhibitor (PI/r) (aHR = 2.4 [1.2, 4.8] p = 0.01). CONCLUSIONS: There is higher frequency of treatment limiting renal impairment events amongst PLHIV receiving TDF in Western India. As TDF scale up progresses, programs need to develop capacity for monitoring and treatment of renal impairment associated with TDF.